Opioid Use Disorder Research Study
Researchers at Johns Hopkins University are conducting a study investigating the potential benefits of psilocybin for opioid addiction treatment.
Fast Facts
Using Non-Prescription Opioids
21-70 Years Old
Compensation Provided
Conducted in Baltimore, MD
Study Background
Outpatient Buprenorphine Induction with Psilocybin for Opioid Use Disorder
The standard-of-care, or usual treatment for opioid use disorder is a medication called buprenorphine. In this research study, we want to find out whether adding psilocybin to regular buprenorphine treatment could result in better treatment outcomes.
Participants will receive either a high or low dose of psilocybin, along with standard buprenorphine therapy. The study will involve screening, assessments, and follow-up visits to evaluate the impact of psilocybin on factors such as drug cravings, quality of life, and treatment retention.
Eventually, the findings of this study might be useful for more effectively treating opioid use disorder and improving people’s quality of life.
Study Background
Outpatient Buprenorphine Induction with Psilocybin for Opioid Use Disorder
The standard-of-care, or usual treatment for opioid use disorder is a medication called buprenorphine. In this research study, we want to find out whether adding psilocybin to regular buprenorphine treatment could result in better treatment outcomes.
Participants will receive either a high or low dose of psilocybin, along with standard buprenorphine therapy. The study will involve screening, assessments, and follow-up visits to evaluate the impact of psilocybin on factors such as drug cravings, quality of life, and treatment retention.
Eventually, the findings of this study might be useful for more effectively treating opioid use disorder and improving people’s quality of life.
Additional Information
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an additional therapy to individuals undergoing standard-of-care outpatient buprenorphine treatment for Opioid Use Disorder. We will measure outcomes including opioid abstinence, adherence to buprenorphine treatment, quality of life, and mood.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 21-70
- Currently using non-prescription opioids
- Interested in starting buprenorphine
- Willing to abstain from psychedelics
- Interested in recovery from opioid use
Preparation:
If enrolled, you will complete four preparatory sessions (either in person or virtually) with a research coordinator and two guides that you will be working with throughout the duration of the study.
Treatment:
Following these visits, there will be one in-person dosing day in which you will randomly receive either the high dose or low dose of psilocybin. You will then meet with the coordinator and guides for follow up visits one day after the dose, and every week thereafter up to 8 weeks (either in person or virtually). There will also be follow up visits at 3 months, 6 months, and 1 year (either in person or virtually).
As a participant, you can receive up to $765 for completing the entire study.
There is no cost for you to participate in our research study.
